HP
ITCI

HealthInvest Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HealthInvest Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-71,138
Closed -$5.94M – 41
2024
Q4 		$5.94M Sell
71,138
-13,440
-16% -$1.1M 2.82% 13
2024
Q3 		$6.19M Buy
84,578
+48,737
+136% +$3.66M 2.91% 14
2024
Q2 		$2.45M Sell
35,841
-2,209
-6% -$153K 1.5% 20
2024
Q1 		$2.63M Buy
38,050
+25,805
+211% +$1.77M 1.6% 25
2023
Q4 		$877K Buy
+12,245
New +$704K 0.69% 31
2022
Q4 		$15.5K Buy
+292
New +$14.6K 0.03% 34

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

HealthInvest Partners's ITCI Position: Q1 2025 in Review

HealthInvest Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 71,138 shares — an estimated $5.94M sold.

HealthInvest Partners first reported a position in ITCI in Q4 2022 and held it in 6 quarters. The position peaked at $6.19M in Q3 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • HealthInvest Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • HealthInvest Partners sold 71,138 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $5.94M.
  • HealthInvest Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 6 quarters.
  • HealthInvest Partners's Intra-Cellular Therapies Inc. position peaked at $6.19M in Q3 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on HealthInvest Partners's 13F filing for Q1 2025, filed 5 May 2025.